Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bausch + Lomb Corporation - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
BLCO
New York
3840
www.bausch.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bausch + Lomb Corporation
Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says
- Oct 8th, 2026 8:51 am
3 Low-Volatility Stocks with Open Questions
- Oct 8th, 2026 2:32 am
Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
- Oct 7th, 2026 8:00 am
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
- Oct 6th, 2026 2:30 pm
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
- Oct 5th, 2026 5:30 am
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
- Oct 1st, 2026 6:00 am
3 Small-Cap Stocks That Concern Us
- Sep 17th, 2026 3:46 am
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026
- Sep 16th, 2026 4:24 pm
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
- Sep 14th, 2026 9:14 am
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
- Sep 11th, 2026 4:11 am
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
- Sep 9th, 2026 7:30 am
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
- Sep 2nd, 2026 5:00 am
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
- Sep 1st, 2026 4:58 am
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers
- Aug 29th, 2026 5:06 pm
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
- Aug 28th, 2026 5:12 am
3 Healthcare Stocks We Steer Clear Of
- Aug 27th, 2026 8:33 am
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
- Aug 26th, 2026 4:11 am
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
- Aug 25th, 2026 10:54 am
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
- Aug 25th, 2026 9:53 am
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
- Aug 24th, 2026 7:01 pm
Scroll